welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
expertly curated content related to this topic
-
Lucio BertarioDr. Lucio Bertario is the Head of the Un...
-
Sherry C. Huang, MDSherry C. Huang is a board-certified ped...
-
Robin K. S. Phillips, MBBS, MS, FRCSRobin K S Phillips is the author of seve...
-
A Roadmap for Navigating Patient AdvocacySo, you and your organization have a pas...
-
Massachusetts General Hospital Cancer CenterThe Gastrointestinal Cancer Genetics Pro...
-
#FamilialAdenomatousPolyposisFAP hashtag for the community...